title: Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation?
abstract: Intensity of pretransplant conditioning has been closely correlated with regimen related toxicity in patients receiving allogeneic bone marrow transplantation (BMT). In this review, we summarize evidence for a direct link between inflammatory reactions induced by irradiation and cytotoxic treatment and occurrence of acute graft-versus-host disease (GvHD) as well as endothelial complications: In our studies, de novo release of TNFalpha during conditioning was associated with an increased risk of severe GvHD and mortality following BMT, whereas increased spontaneous production of IL-10, an endogenous TNF-antagonist, prior to conditioning protected from these complications. Immunogenetic differences in cytokine regulation and costimulation by endotoxin proved to be important cofactors determining the extent of inflammatory cytokine release in individual patients. Pathophysiological relevance of these findings seems to be confirmed by experimental as well as first clinical trials using TNF-antibodies and related antagonists during pretransplant conditioning. Preclinical experiments suggest additional, cytokine independent inflammatory reactions induced by irradiation such as expression of ICAM-1 and endothelial cell apoptosis. Although the exact impact of these findings on pathophysiology of BMT related complications needs further clarification by future studies, conditioning related inflammation as a first crucial step in induction of GvHD and complications has to be considered when designing new protocols for preparation of patients for allogeneic BMT.
authors.affiliation: Med. Klinik III, Klinikum Grosshadern, München, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Holler
authors.forename: B
authors.initials: B
authors.lastname: Ertl
authors.forename: R
authors.initials: R
authors.lastname: Hintermeier-Knabe
authors.forename: M G
authors.initials: MG
authors.lastname: Roncarolo
authors.forename: G
authors.initials: G
authors.lastname: Eissner
authors.forename: F
authors.initials: F
authors.lastname: Mayer
authors.forename: P
authors.initials: P
authors.lastname: Fraunberger
authors.forename: U
authors.initials: U
authors.lastname: Behrends
authors.forename: W
authors.initials: W
authors.lastname: Pfannes
authors.forename: H J
authors.initials: HJ
authors.lastname: Kolb
authors.forename: W
authors.initials: W
authors.lastname: Wilmanns
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000502:physiology*; D006086:Graft vs Host Disease / Q000276:immunology / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D007249:Inflammation; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha